**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript No: 6575**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (12): **Nonalcoholic fatty liver disease**

**Proteomic and genomic studies of non-alcoholic fatty liver disease- clues in the pathogenesis**

Lim JW *et al*. Review of NAFLD pathogenesis

Jun Wei Lim, Michael Miller

**Jun Wei Lim, Michael Miller,** Department of Gastroenterology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom

**Author contributions:** Lim JW and Miller M contributed equally to this paper.

**Correspondence to:** **Michael Miller, MBChB, MRCP,PhD, Specialist Registrar,** Department of Gastroenterology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom. [m.miller@dundee.ac.uk](mailto:m.miller@dundee.ac.uk)

**Telephone:** +44-1382-632307  **Fax:** +44-1382-425504

**Received:** October 24, 2013 **Revised:** January 14, 2014

**Accepted:** April 1, 2014

**Published online:**

**Abstract**

Non-alcoholic fatty liver disease (NAFLD) is a widely prevalent hepatic disorder that covers wide spectrum of liver pathology. NAFLD is strongly associated with liver inflammation, metabolic hyperlipidaemia and insulin resistance. Frequently, NAFLD has been considered as the hepatic manifestation of metabolic syndrome. The pathophysiology of NAFLD has not been fully elucidated. Some patients can remain in the stage of simple steatosis, which generally is a benign condition; whereas others can develop liver inflammation and progress into non-alcoholic steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. The mechanism behind the progression is still not fully understood. Much ongoing proteomic researches have focused on discovering the unbiased circulating biochemical markers to allow early detection and treatment of NAFLD. Comprehensive genomic studies have also begun to provide new insights into the gene polymorphism to understand patient-disease variations. Therefore, NAFLD is considered a complex and mutifactorial disease phenotype resulting from environmental exposures acting on a susceptible polygenic background. This paper reviewed the current status of proteomic and genomic studies that have contributed to the understanding of NAFLD pathogenesis. For proteomics section, this review highlighted functional proteins that involved in: (1) transportation; (2) metabolic pathway; (3) acute phase reaction; (4) anti-inflammatory; (5) extracellular matrix; and (6) immune system. In the genomic studies, this review will discuss genes which involved in: (1) lipolysis; (2) adipokines; and (3) cytokines production.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Non-alcoholic fatty liver disease; Proteomics; Genomics; Metabolic syndrome; Pathophysiology

**Core tip:** Non-alcoholic fatty liver disease (NAFLD) is a widely prevalent hepatic disorder in Western populations. NAFLD can occur as a spectrum diseases, from simple steatosis, to non-alcoholic steatohepatitis characterised by hepatocellular injury and inflammation, to cirrhosis and hepatocellular carcinoma. This paper reviewed the current status of proteomic and genomic studies that have contributed to the understanding of NAFLD pathogenesis. This review highlighted several functional proteins and genetic polymoprhisms; particular those involved in insulin resistance, triglycerides metabolism and hepatic inflammation. It is hoped that this review will offer further insights into the pathophysiology of NAFLD.

Lim JW, Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease- clues in the pathogenesis.

**Available from:**

**DOI:**

# INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a widely prevalent hepatic disorder, affecting up to 30% of the general population of Western countries[[1](#_ENREF_1)]. The term NAFLD comprises an entire pathological spectrum of diseases, ranging from simple steatosis (SS), non-alcoholic steatohepatitis (NASH), progressive inflammation, fibrosis, cirrhosis to hepatocellular carcinoma (HCC)[[2](#_ENREF_2)]. Furthermore, NAFLD has been shown to be closely associated with obesity, insulin resistance, dyslipidemia, type II diabetes mellitus (T2DM) and cardiovascular disease[[2-4](#_ENREF_2)]. Therefore, NAFLD has been considered as the hepatic manifestation of metabolic syndrome (MetS).

In the majority of patients, SS is a relatively benign course. However, SS may evolve into NASH, which is a more aggressive liver disease that tends to be progressive and may lead to cirrhosis[[5](#_ENREF_5)]. The mechanism behind the progression of SS to NASH is still not fully understood. Currently, liver biopsy remains the gold standard in diagnosis of NAFLD. The histological hallmark of NAFLD is lipid accumulation in the hepatocytes in absence of pathologies such as viral hepatitis or alcohol abuse[[4](#_ENREF_4)]. However, liver biopsy is an invasive procedure and the liver is not necessarily uniformly affected in NAFLD[[6](#_ENREF_6),[7](#_ENREF_7)]. Therefore, non-invasive biomarkers for evaluation of liver disease and fibrosis are urgently needed.

Proteomics is a large-scale analysis of protein changes of different patient populations. The identification of specific proteins, either as novel markers or as over/under expressed markers, may have a huge impact by increasing the availability of biomarkers for early diagnosis and therapy[[8](#_ENREF_8)]. On the other hand, genome-wide association (GWA) studies aim to identify the genetic influences on common diseases with common genetic variation of observable traits. The technologies of high-throughput genotyping are able to assay the common single nucleotide polymorphism (SNPs) and relate them to clinical conditions and measurable traits[[9](#_ENREF_9)].

The development of NAFLD is a complex multifactorial process involving the perturbation of multiple gene and protein regulations. Initially, Day and James proposed a “two-hit hypothesis” to explain the concept of steatohepatitis: first hit is the production of steatosis and second hit is the source of oxidative stress capable of initiating significant lipid peroxidation[[10](#_ENREF_10)]. However, the traditional “two-hit hypothesis” has been modified to “multiple parallel hits hypothesis”. The significant overlaps among insulin resistance, hepatic *de novo* lipogenesis and subsequent hepatocyte injury have been proposed to contribute to the progression from SS to NASH[[11](#_ENREF_11)]. Furthermore, numerous candidate gene studies on the effects of genes on the presence of NAFLD and its progression have further supported the “multiple parallel hits hypothesis”[[12](#_ENREF_12)]. This review aims to summarise the current proteomic and genetic studies to provide better understanding about the pathogenesis of NAFLD.

# HEPATIC FIBROGENESIS DEVELOPMENT

Accumulating laboratory evidence suggests that insulin resistance and excess of free fatty acids can trigger the oxidative stress in hepatocytes and lead to chronic inflammation and fibrogenesis[[13](#_ENREF_13),[14](#_ENREF_14)]. Hepatic fibrogenesis is the final consequences of chronic liver disease and constitutes a model of wound-healing process. Regardless of the cause of hepatic damage, hepatic stellate cells (HSCs) are activated within the extracellular matrix (ECM) into myofibroblasts (activated HSCs). These activated HSCs result in the deposition of fibrotic matrix. Hepatic macrophages have been long recognised to be the source of matrix metalloproteinases (MMP) which can degrade the scar tissue in liver[[15](#_ENREF_15)]. The development of fibrogenesis is a dynamic process due to an imbalance in ECM deposition and degradation. Hepatic fibrosis is associated with increased ECM, which include collagen, laminin, hyaluron, elastin and fibronectin. As fibrogenesis progresses, the quantity and composition of ECM changes[[16](#_ENREF_16)]. Therefore, the protein expression may vary at different stages of fibrogenesis due to endogenous adaptive responses. Targeting the optimum levels of different protein expression may shed a light in both disease prediction and disease mechanism.

# PROTEOMIC STUDIES

The advancement of proteomics analysis has provided us with powerful tools for studying NAFLD diagnosis and discovering biomarkers. The first study of serum protein profiles in NAFLD was published by Younossi *et al*[[17](#_ENREF_17)]. The author performed a surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF MS) on 98 obese patients; where 91 patients were diagnosed with NAFLD (12 steatosis alone, 52 steatosis with nonspecific inflammation, 27 NASH) and 7 patients without NAFLD as obese control. The proteomic analysis revealed 12 significant protein peaks. Due to the inherent limitation of low mass accuracy in SELDI-TOF MS, only fibrinogen γ was identified and suggested that it may be related to fibrosis. Later, Bell *et al*[[18](#_ENREF_18)]utilised an ion-intensity based, label-free quantitative proteomics approach (LFQP) and discovered 55 proteins that changed significantly between NAFLD and NASH with advanced fibrosis. Bell *et al*[[18](#_ENREF_18)]further revealed 15 proteins that changed significantly between early NASH and NASH with advanced fibrosis. A 6 proteins diagnostic method (ﬁbrinogen β chain, retinol binding protein 4, serum amyloid P component, lumican, transgelin 2 and CD5 antigen-like) and a 3 proteins diagnostic method (component C7, insulin-like growth factor acid labile subunit and transgelin 2) were developed to diagnose the different stages of NAFLD (AUROC ranging from 0.83 to 0.91). Additionally, alanine aminotransferase (ALT) has been found to be signiﬁcantly inferior in diagnosis the stages of NAFLD (AUROC = 0.53)[[18](#_ENREF_18)]. Several studies have subsequently demonstrated that ALT is a poor NAFLD workup marker and there is no optimal ALT levels to predict advanced fibrosis[[19](#_ENREF_19)]. Despite the lack of single protein in differentiating SS and NASH, *et al*[[18](#_ENREF_18)] have provide an insight into the pathogenesis of NAFLD and NASH. Interestingly, most of the proteins identified in the study were involved in immune system regulation, inflammation, hepatic ECM structure and protein carriers in blood.

## *Protein carriers*

Apolipoproteins, are important structural and functional proteins that transport lipids in blood circulation. As NAFLD is considered the hepatic manifestation of MetS, it is not surprising that apolipoprotein serum levels are altered in patients with chronic liver disease. Previous publications have revealed that the level of ApoA1 decreased with progression of hepatic fibrosis[[20-22](#_ENREF_20)]. A recent proteomic study conducted by Choe *et al*[[21](#_ENREF_21)]using rate nephelometry and particle-enhanced immunonephelometry in non-diabetic patients has concluded that ApoB/ApoA1 ratio was associated with the prevalence of NAFLD and was independent of obesity and other metabolic components. Therefore, ApoB/ApoA1 ratio can be used as a predictable marker for cardiovascular risk in NAFLD patients.

CD5 antigen-like (CD5L) protein, also known as human Sp alpha, is a soluble protein that is expressed by macrophages present in lymphoid tissues and may have an important role in the regulation of the innate and adaptive immune systems[[23](#_ENREF_23)]. A serum proteomic study using 2-dimensional differential in gel electrophoresis (DIGE) was performed on immune depleted sera from 3 groups of patients (pre-cirrhotic NAFLD, cirrhotic NAFLD and cirrhotic NAFLD with co-existing HCC)[[22](#_ENREF_22)].  This study has identified a pattern of serum apolipoproteins (ApoA1, Pro-ApoA1 and ApoA4) and CD5L to distinguish between pre-cirrhotic NAFLD and cirrhotic NAFLD[[22](#_ENREF_22)]. However, CD5L does not increase incrementally with the degree of fibrosis and still falls short as cirrhosis marker with AUC of 0.719[[22](#_ENREF_22)]. Moreover, CD5L is a poor biomarker for HCC. Hence, there could be another trigger factors from the progression of NAFLD, NASH to HCC.

## *Metabolic pathways*

Rodríguez-Suárez *et al* analysed the protein expression of liver samples with DIGE in combination with MALDI TOF/TOF[[24](#_ENREF_24)]. Ten of the proteins were further validated by Western Blot to confirm the observed changes of protein expression[[24](#_ENREF_24)]. This studyhas successfully demonstrated that both serum concentration of carbamoyl phosphate synthase 1 (CPS1) and 78 kDa glucose-regulated protein (GRP78) decreased gradually from cholecystectomy controls with normal liver function and histology subjects to steatosis and NASH patients[[24](#_ENREF_24)]. Further validation of CPS1 and GRP78 in higher number of patients is still warranted. However, this study has provided a useful insight for NAFLD progression.

GRP78, also know as immunoglobulin binding protein (BiP), is a central regulator of endoplasmic reticulum (ER) function, which is crucial for cells survival. GRP78 has been recognised for its roles in protein folding, mis-folded protein targeting for degradation and ER Ca2+ homeostasis[[25](#_ENREF_25),[26](#_ENREF_26)]. Laboratory researches further demonstrated that GRP78 can inhibit both insulin-dependent and ER-stress-dependent SREBP-1c proteolytic cleavage that plays an important role in *de novo* lipogenesis[[27](#_ENREF_27)]. In addition, compelling laboratory evidences have indicated that mitochondrial abnormalities may be involved in the pathogenesis of NAFLD[[28-30](#_ENREF_28)]. CPS1 is a ligase enzyme located in the mitochondria that involved in the production of urea. The down-regulation of CPS1 may lead to an increase of urea, which subsequently becomes uric acid[[31](#_ENREF_31)]. This mechanism could potentially explain the observed significant elevated uric acid levels in NAFLD patient[[32](#_ENREF_32)]. Uric acid has been shown to exert pro-inflammatory and pro-oxidant effect both in adipose tissue and vascular smooth muscle cells[[33](#_ENREF_33)].

A recent largest observational population based cohort of non-diabetic American adult has suggested that uric acid might play a role in NAFLD[[33](#_ENREF_33)]. Sirota *et al*[[33](#_ENREF_33)]revealed that increased serum uric acid levels are associated with greater severity of NAFLD by ultrasonography. Several prospective and retrospective studies have also provided evidences supporting the association of high serum uric acid, the risk of T2DM, cardiovascular diseases and hepatitis[[34-36](#_ENREF_34)]. These have further supported that NAFLD is the hepatic manifestation of MetS.

It has been hypothesised that uric acid may contribute to insulin resistance by inducing local adipose tissue inflammation[[37](#_ENREF_37)]. This may reduced the production of adiponectin, a protein that is involved in glucose haemostasis[[37](#_ENREF_37),[38](#_ENREF_38)]. Furthermore, uric acid may stimulate hepatic lipogenesis, mediated by uric-acid dependent intracelullar and mitochondrial oxidative stress[[33](#_ENREF_33),[37](#_ENREF_37)]. Whether such downstream effects of CPS1 and uric acid play a pathogenic role in NAFLD still requires further laboratory and clinical investigation.

In general, mitochondrial oxidative damage and impaired mitochondrial β-oxidation could contribute to hepatic steatosis. Subsequently, the progressive loss of mitochondrial function in conjunction with ER stress could play a key role in the transition of insulin resistance and NAFLD progression. However, little is known about the spectrum of changes of mitochondrial and ER function and their potential role in the natural history of NAFLD.

## *Acute phase proteins*

An observational study in Japanese population study, high sensitivity C-reactive protein (hs-CRP) serum levels has been reported to be significantly higher in biopsy-proven NASH compared with SS[[39](#_ENREF_39)]. Furthermore, hs-CRP levels were significantly elevated in advanced NASH compared with those with mild NASH[[39](#_ENREF_39)]. However, the role hs-CRP in differentiating severity of NASH remains controversial. Zimmermann *et al*[[40](#_ENREF_40)]demonstrated a strong positive association between BMI and hs-CRP levels, which were measured with nephelometry, throughout the broad range of obesity. However, there were no signiﬁcant associations between inﬂammation or ﬁbrosis, respectively and hs-CRP observed[[40](#_ENREF_40)].

Serum haemoglobin levels have been observed to be significantly elevated in extremely obese NAFLD patient and shown to be significantly associated with prevalence of NAFLD[[41-43](#_ENREF_41)]. Yu *et al*[[42](#_ENREF_42)]performed a serum protein ﬁngerprint analysis, utilising the SELDI-TOF-MS technique combined with bioinformatic approaches and discovered that haemoglobin subunit alpha was significantly up-regulated in NAFLD group. It has been proposed that the relationship between serum haemoglobin and NAFLD may be partially modulated by haptoglobin (Hpt), an α2-glycoprotein acute phase protein produced in response to an inflammatory insult[[44](#_ENREF_44)]. Serum haemoglobin levels may be a marker of hepatic steatosis but not of severity of NAFLD in obese patients.

Acute phase proteins are the key to the hepatic innate defences against insults and reduce hepatic tissue damage. Therefore, acute phase proteins may have an immediate role in hepatocytes injuries and could be used as NAFLD predictive markers in obese patients. However, the concentration of acute phase proteins does not reflect the severity of disease, suggesting different protein mechanism for NAFLD progression.

A recent study by Kamada *et al*[[44](#_ENREF_44)] has shed a light into the role of acute phase protein and progression of NAFLD. Kamada *et al*[[44](#_ENREF_44)]utilised lectin antibody enzyme-linked immunosorbent assay (ELISA) and demonstrated that serum fucosylated haptoglobin (Fuc-Hpt) underwent a stepwise increased with increasing hepatocyte ballooning scores in biopsy-proven NAFLD patients (AUROC ranging from 0.724 to 0.759). Fucosylated alpha-fetoproteins have been previously shown to be more selectively secreted into bile [[45](#_ENREF_45)]. Kamada *et al*[[44](#_ENREF_44)] hypothesised that an increase in ballooning hepatocytes could lead to the disruption of the fucosylation-based machinery and subsequently an increased secretion of Fuc-Hpt into the serum.

Pentraxin 3 (PTX-3), another acute-phase protein that resembles CRP in function and a possible modulator of complement system has been used as the marker for disease severity in cardiovascular, inflammatory and infectious diseases[[46](#_ENREF_46)]. Yoneda *et al*[[47](#_ENREF_47)]measured plasma PTX-3 levels with ELISA in biopsy-proven NAFLD, based on the method of Brunt. This study revealed a profound elevation of plasma PTX-3 levels in NASH and further suggested that PTX-3 could be a promising clinical marker for fibrosis severity in NASH[[47](#_ENREF_47)].

CRP and serum amyloid protein belong to the short pentraxins group, which have reported to be produced by the liver as a systemic response to local inflammation. On the other hand, PTX-3 is the prototypic long pentraxin, which is produced in damaged tissue and in response to proinflammatory stimuli such as interleukin 1β (IL-1β) and tumour necrosis factor-α (TNF-α). It has been anticipated that PTX-3 expression pattern may be more tissue specific than CRP[[47](#_ENREF_47),[48](#_ENREF_48)]. However, conflicting studies have been published regarding the association of PTX-3 levels, hs-CRP levels and the severity of MetS[[48](#_ENREF_48)]. Further validation of PTX-3 is warranted to assess the usefulness of PTX-3 in understanding NAFLD.

## *Anti-inflammatory and anti-oxidants*

A large cross-sectional study has demonstrated the inverse relationship between total serum bilirubin levels with vanadate oxidation method and the prevalence of NAFLD independent of known metabolic risk factors[[49](#_ENREF_49)]. Similar inverse relationship of NAFLD was discovered with conjugated and unconjugated bilirubin respectively[[50](#_ENREF_50),[51](#_ENREF_51)]. In addition, serum bilirubin has been long recognised to have an inverse relationship with the development of coronary artery disease[[52](#_ENREF_52)].

Bilirubin is the metabolic end product of heme catabolism as haemoxygenase-1 (HO-1), a stress-responsive protein that degrades the pro-oxidant heme to biliverdin. Subsequently, biliverdin reductase reduces biliverdin to bilirubin[[53](#_ENREF_53)]. The intrinsic amplification properties of biliverdin reductase redox cycle could readily augment the antioxidant effects of bilirubin by 10,000-fold[[54](#_ENREF_54)]. The interesting challenge here is to link the clinical studies, which focus on serum levels of bilirubin with molecular mechanisms to understand the pathogenesis of NAFLD.

Recent cardiovascular research that focused on HO-1 activation in rat model of chronic heart failure has demonstrated significant improved survival due to the reduction in leukocyte activation and cardiomyocytes apoptosis. Furthermore, chronic HO-1 activation has shown to suppress the elevated levels of myeloperoxidase (MPO) activity, IL-1β production and TNF-α production[[53](#_ENREF_53)]. Li *et al*[[55](#_ENREF_55)] characterised the expression of HO-1 in biopsy specimens of normal and active cirrhosis liver specimen with immunohistochemistry; and cultured human hepatic myofibroblasts with Northern and Western blot analysis. Li *et al*[[55](#_ENREF_55)]discovered that HO-1 can inhibit the proliferation of hepatic myoﬁbroblasts. Therefore, it is anticipated that bilirubin can inhibit the pathogenesis of NAFLD and NASH through the potent antioxidant, anti-inﬂammatory and anti-ﬁbrogenic effects. Further research is needed to elucidate the mechanisms underlying this association and to establish the role of serum bilirubin as a potential protective marker for NAFLD risk.

## *Extracellular matrix*

While the presence of inﬂammation is due to lipid accumulation, an imbalance of ECM production and degradation will therefore lead to fibrogenensis. The association of serum concentration of ECM components, especially increased serum hyaluronic acid, type IV collagen 7S and laminin levels measured with routine laboratory parameters and the degree of fibrosis in NAFLD have been studied extensively[[56-59](#_ENREF_56)]. Hyaluronic acid is a component of ECM, which synthesised by mesenchymal cells. The increased production and delayed clearance of hyaluronic acid have been demonstrated to be associated with the severity of hepatic inflammation[[56](#_ENREF_56)]. Type IV collagen is the main collagen component of basement membrane whereas laminin is the main non-collagenous glycoprotein of the ECM that deposited in the space of Disse during sinusoidal capillarisation[[58](#_ENREF_58),[60](#_ENREF_60)]. It is believed that hepatocytes ballooning and releases of type IV collagen and laminin are the main causes of increased their serum levels. However, the mechanism of this interaction is still unknown.

It is important to note that hyaluronic acid, type IV collagen 7S and laminin have been shown to increased in cases of fibrosis resulting from alcoholic, primary biliary cirrhosis and chronic viral hepatitis[[56](#_ENREF_56),[61](#_ENREF_61),[62](#_ENREF_62)]. Therefore, hyaluronic acid, type IV collagen 7S and laminin may be useful in detecting the presence of severe fibrosis in chronic liver disease, but not specific to NAFLD.

Lumican, a highly biologically active 40-kDa keratin sulfate proteoglycan member of the leucine-rich repeat protein superfamily, is known to be progressively over-expressed with the increasing severity of NAFLD and NASH[[63](#_ENREF_63),[64](#_ENREF_64)]. Similar to the liver, the maintenance of myocardial ECM and regulation of fibrotic myocardial remodelling are essential for normal cardiac physiological function[[65](#_ENREF_65)]. A recent cardiac failure research discovered that lumican production is induced by a combination of inﬂammation and mechanical stimuli from cardiac ﬁbroblasts[[66](#_ENREF_66)]. Further laboratory research also revealed that in the absence of lumican, hepatocytes are protected against fibrosis despite ongoing injury[[64](#_ENREF_64)]. Therefore, lumican might have an important role in tissue remodelling and contribute to ﬁbrogenesis.

ECM degradation occurs predominantly as a consequence of the action of MMPs[[67](#_ENREF_67)]. MMPs has been known to be an important regulatory enzyme in inflammatory process to modulate leukocyte influx, either through regulation of barrier function, cytokine or chemokine activity, or gradient formation[[68](#_ENREF_68)]. An up-regulation of tissue inhibitors of metalloproteinases (TIMPs) in liver fibrosis may impair MMPs’ activity and lead to altered ECM production[[69](#_ENREF_69)]. Interestingly, a growing body of evidences has demonstrated MMPs’ role in liver fibrogenesis[[67](#_ENREF_67),[69](#_ENREF_69)]. Serum MMP-1 level assayed by ELISA has been found to be negatively correlates with the severity of fibrosis whereas MMP-1 mRNA quantified with spectrophotometer and single reverse transcription polymerase chain reaction (PCR) has been found to be elevated in liver tissue as fibrosis progressed[[70](#_ENREF_70),[71](#_ENREF_71)]. The decreased synthesis of MMP-1 is believed to due to HSC apoptosis or necrosis. However, the link between increased hepatic MMP-1 expression and decreased serum MMP-1 remained unanswered.

Notable increase in serum MMP-9 level with ELISA was found in NASH and hepatitis C infected patients[[72](#_ENREF_72)]. Furthermore, immunohistology of the liver specimen and revealed a striking difference of the immunolabelling patterns between NASH and hepatitis C infected liver[[72](#_ENREF_72)]. Hepatitis C infected liver demonstrated an essentially localised labelling in the cytoplasm of hepatocytes, biliary canaliculi and bile ducts whereas NASH liver demonstrated a discrete labeling of neutrophil subpopulation[[72](#_ENREF_72)]. The difference of MMP-9 patterns suggested a different pathophysiological involvement of this protease in the ﬁbrogenesis underlying different etiology.

On the other hand, Wanninger *et al*[[67](#_ENREF_67)]utilised sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blot analysis in primary human hepatocytes, steatosis human hepatocytes and murine NASH hepatocytes to study the activity of MMP-9. Wanninger *et al*[[67](#_ENREF_67)]concluded that MMP-9 activity is associated with hepatic inflammation and fibrosis but not with hepatic steatosis and body weight. This raises the question of peripheral adipocytes involvement with other inflammatory mediators that could have contributed to the progression of NAFLD and NASH. Furthermore, Wanninger *et al*[[67](#_ENREF_67)] revealed a negative correlation of MMP-9 activity with serum adiponectin in murine NASH models. This finding highlighted the role of inflammation in the progression of NAFLD. The anti-inflammatory activity of adiponectin will be further discussed in the genomic section.

A study utilising reverse transcription and quantitative real-time reverse transcription PCR in animal models has demonstrated an accumulation of macrophages and increased gene expression of MMP-12, MMP-13 and TIMP-1 in predominantly adipose tissue compared with liver tissue[[73](#_ENREF_73)]. The author proposed that attenuated hepatic MMP expression in both livers and adipose tissue might be responsible for the shifting balance of fibrogenesis[[73](#_ENREF_73)]. However, the key source of these enzymes and tight relationship between adipose tissue dysfunction and developments of hepatic ﬁbrosis remain unclear.

Despite the growing understanding of MMPs and TIMPs, the conclusive role of each MMPs and TIMPs subtypes in appropriate human model is still limited. However, this review highlighted the increased recognition of liver fibrosis as dynamic pathological process that involves both progression and regression of ECM.

## *Immune cells and cytokines*

A paper by Zhan and An has comprehensively reviewed the role of liver innate immune cells such as T helper cells (Th cells), activated kupffer cells (KC) and natural killer T (NKT) cells in the development of NAFLD[[74](#_ENREF_74)]. Hereby, we further reviewed related cytokine papers that being published later.

It has been long proposed that it was Th1 cytokine excessive production in NAFLD results in hepatic insulin resistance and NASH [[74](#_ENREF_74)]. However, a recent laboratory research on C57BL/6 and Balb/c mice with mRNA extraction and real-time PCR demonstrated that imbalance between Th1 and Th2 did not account for the increased NASH severity and suggested that macrophage responses are the important contributors to NAFLD progression[[75](#_ENREF_75)]. In addition, cytokines are not only being produced by local sources but also by peripheral blood cells. The presence of an altered phenotype and functionality of circulating immune cells has been speculated to be a distinctive characteristic in NASH patients[[76](#_ENREF_76),[77](#_ENREF_77)].

Innate immune cells have the ability to secrete cytokines and to promote influx of inflammatory cells. To date, emerging strong evidences suggested that cytokines such as TNF-α and interleukin-1 (IL1) are sensitising factors acting upon leukocyte infiltration of the liver[[76](#_ENREF_76),[78](#_ENREF_78)]. These cytokines and chemokines effects contributed to intracellular oxidative stress and mitochondrial dysfunction, which amplified hepatocytes damage. The cytokines mechanism appears to be like a vicious cycle. The further disrupted cellular mitochondrial respiratory chain can thereby cause the formation reactive oxidative species of nearby hepatocytes[[76](#_ENREF_76)]. As a consequence, HSCs is activated and lead to hepatic fibrosis. The development and progression of NASH act in a cooperative manner with pro-inflammatory cytokines.

Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been studied extensively for its wide range of biological function. IL-6 has been proposed to have direct and indirect deleterious role such as induction of inflammation, hepatoprotector, regulators of acute phase response and insulin signalling[[79](#_ENREF_79)]. Wieckowska *et al* demonstrated a markedly increased hepatic IL-6 expression assayed with immunohistochemistry in patients with NASH as compared to SS or normal liver[[80](#_ENREF_80)]. The hepatic IL-6 expression in this study cohort has showed to be correlates with the severity of inflammation and fibrosis[[80](#_ENREF_80)]. At the same time, a positive correlation was observed between the plasma IL-6 levels measured with ELISA and hepatic IL-6 expression[[80](#_ENREF_80)]. However, discrepant results have been reported regarding IL-6 in NAFLD studies. Haukeland *et al*[[81](#_ENREF_81)]determined IL-6 in 47 biopsy-proven NAFLD and 30 controls with enzyme immunoassays and revealed no significant changes in NASH group compared to SS.

Interestingly, Haukeland *et al*[[81](#_ENREF_81)]further evaluated serum level of CC-chemokine ligand 2 /monocyte chemo-attractant protein-1 (CCL2/MCP1) and demonstrated an increasing levels from healthy controls to SS and reached the highest levels in NASH. It has been proposed that an increased circulating CCL2/MCP-1 levels may be related to the development of NASH[[79](#_ENREF_79),[81](#_ENREF_81)]. CCL2, an acute and chronic phase chemokine has been known to be secreted by HSCs. CCL2 is responsible for monocyte and macrophage infiltration of liver and maintaining hepatic inflammation and fibrogenesis[[82](#_ENREF_82)]. On the other hand, MCP-1 is known to be derived from visceral adipose tissue and reached liver via portal circulations[[83](#_ENREF_83)]. Many more studies are still warranted to understand the pivotal roles of CCL2 and MCP-1 in the development of inflammatory responses in the liver. The lipid accumulation from visceral tissue and hepatocellular could significantly contribute to the expression of CCL2 and MCP-1. Therefore, the concentrations of both chemokines are crucial for the recruitment of immune cells to sites of inflammation.

It is believed that adipose tissue-derived cytokine could also affects liver innate immune cells[[74](#_ENREF_74)]. With LFQP approach, Bell *et al*[[18](#_ENREF_18)] demonstrated that retinol binding protein 4 (RBP4), an adipokine that associated with insulin resistance and T2DM was significantly decreased in expression with increasing NAFLD severity. Utilising ELISA, Alkhouri *et al*[[84](#_ENREF_84)]also demonstrated an inverse relationship between RBP4 and liver fibrosis. However, there were also contrary reports that demonstrated significantly elevated serum RBP4 in NAFLD patients[[85](#_ENREF_85),[86](#_ENREF_86)]. The lack of consistency prompted us to re-evaluate RBP4 as a potential novel marker to assess the progression of fibrogenesis in NAFLD.

On the other hand, the link between RBP4 and T2DM are more obvious. Graham *et al*[[87](#_ENREF_87)] revealed an increased serum RBP4 with ELISA in patients with T2DM and a decreased expression of glucose transporter 4 (GLUT4). The mechanism behind this remains unclear, but raises the possibility of adipocytes involvement in glucose sensing. A nicely summarised review article by Christou *et al*[[88](#_ENREF_88)]indicated that RBP4 might have the ability to induce insulin resistance in an autocrine or paracrine mechanism in the adipose tissue. It is noteworthy that circulating RBP4 can be influenced by non-metabolic condition such as renal failure and intervention such as anti-diabetic drugs and exercise[[88](#_ENREF_88),[89](#_ENREF_89)]. Therefore, the association of RBP4 level and MetS could be affected and should be interpret with caution. The pathogenic role of RBP4 has contributed to genetic studies of RBP4 locus in human chromosome 10q, which have been linked to hyperinsulinemia or early onset T2DM[[89](#_ENREF_89)]. The polymorphism of RBP4 gene polypmorphism has been linked with the development of T2DM and obesity in different populations[[89](#_ENREF_89),[90](#_ENREF_90)]. However, the associations among RBP4 polymorphism, serum RBP4 levels and measures of MetS have not been universally described[[90](#_ENREF_90)].

# GENOMIC STUDIES

The first GWA study was performed by Romeo *et al* using a phenotype based on magnetic resonance spectroscopy. The authors identified that an allele in human patatin-like phospholipase domain containing 3 gene (PNPLA3) (rs738409; I148M) was strongly associated with increased hepatic lipids levels and hepatic inflammation. This study importantly raised that genetic factors could account towards the susceptibility of NAFLD[[91](#_ENREF_91)]. With regards to the pathophysiology of NAFLD, variations in genes involved in hepatic lipid metabolism, ECM balance, cytokins and insulin resistance will be discussed in this review.

## *Genes that affect lipolysis*

Polymorphisms of PNPLA3 gene have been found to be strongly associated with the pathogenic status of NAFLD in different populations[[91-93](#_ENREF_91)]. PNPLA3 gene, encoding adiponutrin is known to have lipase activity *in vitro* and has been found to be involved in glucose and lipid metabolism[[91](#_ENREF_91)]. Despite several publications on the association between PNPLA3 polymorphisms and NAFLD, the physiological functions of the PNPLA3 still remain unclear.

A well-conducted meta-analysis revealed that GG genotype of PNPLA3 (rs738409; I148M) exerts a stronger effect on hepatic lipids accumulations and patients with GG phenotype are more susceptible to aggressive disease associated with higher fibrosis scores than CC genotype[[94](#_ENREF_94)]. Furthermore, Sookoian *et al*[[94](#_ENREF_94)] found no correlation between increased liver disease severity and heterozygous or homozygous mutants of G-allele.

The link between NAFLD stage and PNPLA3 is well established, but the association of insulin resistance and obesity with PNPLA3 are less clear[[95](#_ENREF_95),[96](#_ENREF_96)]. A recent review of PNPLA3 polymorphism suggested that PNPLA3 is more likely to influence lipid content and liver disease severity but not insulin resistance[[95](#_ENREF_95)]. Lallukka *et al*[[97](#_ENREF_97)]demonstrated that NAFLD patients with polymorphism of PNPLA3 is not characterised by adipose tissue inflammation, insulin resistance and features of the metabolic syndrome such as hyperinsulinaemia, hypertriacylglycerolaemia and a low HDL-cholesterol concentration. Despite the less clear relationship in insulin resistance, the severity of NAFLD has been proven to be related to the PNPLA3 in T2DM populations. Therefore, screening analysis of the PNPLA3 polymorphism could still be useful to select T2DM patients who need specific interventions as prevention for NAFLD[[98](#_ENREF_98)].

A recent transplant research revealed that PNPLA3 of non-CC genotype is associated with post-transplant obesity but not independently with diabetes. Furthermore, the donor genotypes were not associated with obesity or diabetes[[99](#_ENREF_99)]. This research highlighted the potential of peripheral mechanism for insulin resistance and could reflect a multi-factorial gene involvement in NAFLD. One point to note is that the effect on allograft steatosis was not studied.

Ample evidences exist in the literatures that triglycerides (TG) accumulation in liver is a result of obesity and diabetes[[100](#_ENREF_100)]. Surprisingly, an accumulation of TG has been suggested to be a protective mechanism to prevent progressive liver damage in NAFLD[[101](#_ENREF_101)]. Adipose tissue triglyceride lipase (ATGL) has been found to be a rate-limiting enzyme for degradation of TG and has been implicated in the pathogenesis and progression of NAFLD. A deﬁciency of ATGL was proposed to lead to TG accumulation in many organs, including the liver[[102](#_ENREF_102),[103](#_ENREF_103)]. In murine model, ATGL knock out (ATGL-KO) mice demonstrated increased hepatic lipids accumulation during induced-ER stress but suppressed gene expression of inﬂammatory markers. Further evaluation suggested that an enrichment of oleic acid in the TG pool plays the main role for ATGL in protection from potentially harmful consequences of ER stress[[103](#_ENREF_103)]. Furthermore, ATGL-KO animal model demonstrated a high insulin sensitivity despite liver TG storage[[102](#_ENREF_102)]. Therefore, the progressions of NAFLD in obese and diabetes patients have a distinguishable phenotypic imprint on the hepatocyte lipidome. Further research in ATGL polymorphism and lipidome could potential elucidates the lipolytic catabolism pathway in NAFLD.

Apolipoprotein C3 (ApoC3) is the most important components of very low density lipoprotein (VLDL). ApoC3, also a strong inhibitor lipoprotein lipase (LPL) has been found to enhance fatty acid uptake from plasma TG in adipose tissue in mice[[104](#_ENREF_104)]. Therefore, a deficiency of ApoC3 could leads to higher susceptibility to diet-induced obesity followed by more severe development of insulin resistance[[104](#_ENREF_104)].

Approximately between 50% and 75% of patients with T2DM have fatty liver diagnosed by ultrasound[[4](#_ENREF_4)]. Insulin resistance has been anticipated to play a major role in the pathogenesis of T2DM and may enhance hepatic fat accumulations by increasing free fatty transportation due to the effect of hyperinsulinemia to stimulate anabolic process[[4](#_ENREF_4),[105](#_ENREF_105)]. Petersen *et al*[[105](#_ENREF_105)]demonstrated a 3- to 4-fold increased in prevalence of insulin resistance in Asian-Indian men compared with Caucasian men. Later, Petersen *et al*[[106](#_ENREF_106)]further demonstrated that the polymorphisms of ApoC3 (C-482T and T-455C) are associated with NAFLD and insulin resistance in Indian men. However, there is a contrary report suggested that the genetic variants in ApoC3 does not contribute to NAFLD in Finnish populations[[107](#_ENREF_107)]. The reason regarding the divergent results remains unknown but importantly highlighted the ethnic differences in disease susceptibility.

Given the essential contribution of lipogenesis pathway, another common gene variant, glucokinase regulatory protein (GCKR) gene has been studied extensively[[108-110](#_ENREF_108)]. GCKR regulates glucokinase, a phosphorylating enzyme that responsible for hepatic glucose metabolism and activates hepatic lipogenesis[[108](#_ENREF_108)]. Polymorphism of GCKR was found to be signiﬁcantly associated with increased risk of T2DM, particularly in Asian population[[109](#_ENREF_109),[110](#_ENREF_110)]. Furthermore, polymorphism of GCKR (rs780094 and rs1260326) has been shown to be associated with NAFLD in Chinese people and obese youth respectively[[108](#_ENREF_108),[111](#_ENREF_111)]. In addition, Tan *et al*[[112](#_ENREF_112)]further suggested that the interactions of GCKR and PNPLA3 genes can increase susceptibility to NAFLD.

The protein peroxisome proliferator-activated receptor gamma coactivator 1-alpha PGC-1α), encoded by the PPARGC1A gene, has also been recognised to be the transcriptional co-activator of peroxisome proliferator actived receptor gamma (PPAR-γ) gene[[113](#_ENREF_113)]. The PGC-1α and PPAR-γ pathway play a central role in energy metabolism, mitochondrial biogenesis and function, oxidative phosphorylation, gluconeogenesis and lipogenesis and induction of apoptosis[[113](#_ENREF_113),[114](#_ENREF_114)]. PPARGC1A knock outmice have been reported to develop hepatic steatosis, as a result of the combination of reduced mitochondrial respiratory capacity and increased expression of lipogenic genes[[115](#_ENREF_115)]. However, the role of PCG-1α in MetS is less clear than PPAR-γ.

Controversial reports exist in the literatures, regarding PPARGC1A gene in patient’s susceptibility for NAFLD. Hui *et al*[[116](#_ENREF_116)]demonstrated that only polymorphism of PPAR-γ (C161T) are associated with NAFLD susceptibility possibly through the adiponectin pathway, not PPARGC1A gene. Subsequent reports demonstrated that PPARGC1A (rs8192678) risk A allele is associated with an increased risk of NAFLD and is independent of the effect of the PNPLA3 (rs738409) polymorphism in Taiwanese obese children population[[117](#_ENREF_117)]. The role of PCG-1α remains unclear but has been hypothesised to be associated with exercise[[118](#_ENREF_118)]. On the other hand, the genetic variation in PPAR-γ (Pro12Ala and C1431T) has been studied extensively in different ethic cohorts[[119-121](#_ENREF_119)]. Polymorphism of PPAR-γ has been concluded to be strongly associated with NAFLD whereas polymorphism of G allele in PPAR-γ gene (rs10865710) is only associated with lobular inflammation[[119](#_ENREF_119)].

## *Genes that affect adipokines*

Adipocytes play multiple endocrine roles in the body. As body mass index (BMI) increases, the metabolic role of adipocytes changes[[122](#_ENREF_122)]. An increased understanding of the role of the adipocyte and its associated adipokines could give us some clues in understanding MetS and NAFLD.

Adiponectin is the most abundant and adipose-speciﬁc adipokine. Contrary to other adipokines, adiponectin correlates negatively with BMI, insulin resistance, plasma TG, LDL-cholesterol, hepatic fat content and progression to NASH in NAFLD patients[[38](#_ENREF_38),[123](#_ENREF_123)]. Adiponectin has been reported to be higher in women and in Caucasian compared with Asian or African individuals[[123](#_ENREF_123),[124](#_ENREF_124)].

Adiponectin is known to have insulin-sensitising, antifibrogenic and anti-inflammatory properties. Studies have found that Adiponectin is involved in the activation of AMPK and downregulates the expression of sterol regulatory element-binding protein 1c (SREBP1c), a transcription factor that regulates cholesterol and lipid synthesis. As a result, this lead to decreased gluconeogenesis, decreased free fatty acid influx into the liver, increased free fatty acid oxidation and decreased *de novo* lipogenesis[[38](#_ENREF_38),[125](#_ENREF_125)]. Two common SNPs in Adiponectin gene (45GT and 276GT) have been found to be significantly associated with the presence of NAFLD in non-obese, non-diabetic and normolipidemic patients and were subsequently correlated to the severity of NASH. Furthermore, Adiponectin gene (45GT and 276GT) has been proven to be the acute modulation of postprandial adiponectin levels and lipoprotein responses after fat ingestion[[126](#_ENREF_126)].

However, controversy exists in the literatures. Some authors have reported a lack of association between Adiponectin gene and NAFLD[[38](#_ENREF_38),[127](#_ENREF_127)]. Furthermore, several studies demonstrated a weak association between adiponectin gene polymorphism and cardiovascular disease[[128](#_ENREF_128),[129](#_ENREF_129)]. The association between adiponectin polymorphisms and T2DM has been inconsistent and recent meta-analysis concluded that adiponectin gene polymorphism does not influence the development of T2DM[[130](#_ENREF_130),[131](#_ENREF_131)]. Interestingly, two recent meta-analyses have revealed the potential protective factor of Adiponectin gene of different allele for cancer risk[[132](#_ENREF_132),[133](#_ENREF_133)]. One point to note was that these meta-analyses were not specific to liver aetiology. However, recent evidences demonstrated a correlation between NAFLD and colorectal cancer[[134](#_ENREF_134)]. The mechanism behind this remains unknown but raises the possibility of Adiponectin’s anti-inflammatory effect that suppress TNF-α and other proinflammatory cytokines[[38](#_ENREF_38)]. Further research is warranted to elucidate the link between cytokines and progression of NAFLD.

Leptin (LEP), an adipocyte-derived hormone exerts its action through leptin receptor (LEPR), a single-transmembrane-domain receptor of the cytokine-receptor family has been shown to be responsible for satiety and energy homeostasis[[135](#_ENREF_135),[136](#_ENREF_136)]. LEP and LEPR mutations have been shown to be strongly associated with obesity and endocrine dysfunction[[135](#_ENREF_135),[137](#_ENREF_137)]. In study of NAFLD, Leptin-deficient Ob/Ob mouse has demonstrated a dramatic up-regulations of hapetic *de novo* lipogenesis markers and a significant impairment in hepatic mitochondrial function[[138](#_ENREF_138)]. Recently, an association between variants of LEPR and PNPLA3 has been reported. The interactions between LEPR and PNPLA3 genes showed an increased risk of NAFLD compared to either gene alone[[139](#_ENREF_139)].

## *Genes that affect cytokines production*

Little is known about the evolvement of NAFLD, a relative benign condition to NASH, an irreversible inflamed stage of liver disease. Inflammatory cytokines has been proposed to play a central role in the progression of NAFLD[[140](#_ENREF_140)]. Cytokines are central mediators of hepatic inflammation, cells apoptosis and cells regeneration. TNF-α and IL-6 have been found to be the initial cytokines chemokines that being produced after hepatic insults[[140](#_ENREF_140),[141](#_ENREF_141)].

TNF-α has been known to interact between fat accumulation and hepatic inflammation[[141](#_ENREF_141)]. Coulon *et al*[[141](#_ENREF_141)]suggested that TNF-α was significantly higher in NASH patients compared to SS patients. This highlighted the potential role of TNF-α in NASH. Furthermore, a recent meta-analysis has demonstrated that polymophisms of TNF-α (-238) is particularly associated with the susceptibility to NAFLD[[142](#_ENREF_142)]. TNF-α has also been previously known to be an important cytokine that regulates insulin resistance by affecting insulin receptor substrate-1 (IRS-1) and insulin receptor kinase (IRK) in the insulin signal transduction pathway[[142](#_ENREF_142)]. Nevertheless, the involvement of TNF-α in insulin resistance is debatable. Polymorphisms in gene such as IRS-1 (972 Arg) and ectoenzyme nucleotide pyrophosphate phosphodiesterase 1 (ENPP1) that directly affect insulin receptor activity have demonstrated that insulin resistance does contribute to the progression of NAFLD[[143](#_ENREF_143)]. However, a recent study by Aparicio-Vergara *et al*[[144](#_ENREF_144)] demonstrated a disassociation of TNF-α induced hepatic inflammation and insulin resistance.

IL-6 is another cytokine that involved in the regulation of several cellular processes and has been demonstrated to be associated with NASH in several ethic cohorts[[141](#_ENREF_141),[145](#_ENREF_145)]. However, the polymorphism of G/C allele is questionable. Carulli *et al*[[146](#_ENREF_146)]*.* demonstrated that polymorphism of IL-6 −174C is more prevalent in NAFLD and associated with insulin resistance while other studies demonstrated that polymorphism of C allele was unlikely to associate with insulin resistance[[145](#_ENREF_145)]. Hence, insulin resistance and augmentation of hepatic inflammation could be modulated by other factors than TNF-α and IL-6.

# CURRENT KNOWLEDGE

There is no doubt that there is a complex interplay between the body environment, predispose genetics and external environment (diet) for the development and progression of NAFLD. From the literatures, we know that NAFLD is characterised by insulin resistance, metabolic hyperlipidaemia and hepatic inflammation (Tables 1 and 2). Insulin resistance, accumulation of lipids (both visceral and hepatocellular) and persistent hepatic inflammation can result in a complex biochemical interaction. This could alter the cytokine profile and cell biology. A resultant disequilibrium in lipid homeostasis leads to hepatocellular lipid accumulation and an increase in oxidative stress due to mitochondrial dysfunction. Many studies have shed light on the role inflammation in progression of NAFLD to NASH. The activation of cell death pathways such as apoptosis and necrosis has redundant roles in further triggering liver damage and fibrosis.

One of the crucial aspects from this review is that promising anti-inflammatory and innate immune mediators such as bilirubin, TNF-α and IL-6 are also commonly associated with cardiovascular disease, obesity and diabetes mellitus. The background of MetS further confounds these shared observations. An increased understanding of the roles of the liver in metabolic diseases or vice versa could lead to development of improved targeted strategies for disease prevention and treatment.

This review also highlighted a considerable disease variation exists in the prevalence and severity of NAFLD. Therefore, suggesting that the risk of morbidity and mortality that might be influenced by a combination of genetic and environmental factors, which has strongly proven by the PNPLA3 polymorphisms. The improve understanding and further identification of genetic polymorphisms could lead to two potential applications for clinical practice. Firstly, genetic biomarkers could allow early disease diagnosis of higher risk individuals or family. Secondly, genetic biomarkers could potentially lead to the development of novel preventive and targeting measures of NAFLD.

# CONCLUSION

Advances in proteomic technologies have contributed to the discovery of clinically important protein biomarkers, which are the key molecules that reflect biological reactions. Extensive literature searches revealed several potential serum protein markers that could differentiate NAFLD and NASH. Further validations of these proteins markers in larger cohorts are required to reflect the degree of hepatic fibrosis. In addition, genomic studies have further revealed the importance of genetic polymorphisms in various steps of the pathogenesis of NAFLD. Clearly, unfavourable genetic polymorphism coupled with unfavourable biological environment can increase a patient’s susceptibility to the development of NAFLD and its progression to NASH. In general, further breakthrough and investigation of changes in protein expression levels are still warranted to understand the pathophysiology of NAFLD.

**REFERENCES**

1 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]

2 **Qureshi K**, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. *World J Gastroenterol* 2007; **13**: 3540-3553 [PMID: 17659704]

3 **Bellentani S**, Bedogni G, Tiribelli C. Liver and heart: a new link? *J Hepatol* 2008; **49**: 300-302 [PMID: 18554746 DOI: 10.1016/j.jhep.2008.05.003]

4 **Utzschneider KM**, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. *J Clin Endocrinol Metab* 2006; **91**: 4753-4761 [PMID: 16968800 DOI: 10.1210/jc.2006-0587]

5 **Miele L**, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). *Transl Res* 2007; **149**: 114-125 [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011]

6 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; **55**: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]

7 **Bedossa P**. Current histological classification of NAFLD: strength and limitations. *Hepatol Int* 2013; 7: 765-770 [DOI: 10.1007/s12072-013-9446-z]

8 **Pandey A**, Mann M. Proteomics to study genes and genomes. *Nature* 2000; **405**: 837-846 [PMID: 10866210 DOI: 10.1038/35015709]

9 **Manolio TA**, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. *Annu Rev Med* 2009; **60**: 443-456 [PMID: 19630580 DOI: 10.1146/annurev.med.60.061907.093117]

10 **Day CP**, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998; **114**: 842-845 [PMID: 9547102]

11 **Yilmaz Y**. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? *Aliment Pharmacol Ther* 2012; **36**: 815-823 [PMID: 22966992 DOI: 10.1111/apt.12046]

12 **Hernaez R**. Genetics of non-alcoholic fatty liver disease and associated metabolic disorders. *Avances en Diabetología* 2011; **27**: 186-97 [DOI: 10.1016/j.avdiab.2011.11.004]

13 **Asrih M**, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. *J Endocrinol* 2013; **218**: R25-R36 [PMID: 23833274 DOI: 10.1530/joe-13-0201]

14 **Lucchesi AN**, Freitas NT, Cassettari LL, Marques SF, Spadella CT. Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease. *Acta Cir Bras* 2013; **28**: 502-508 [PMID: 23842931]

15 **Friedman SL**. Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis. *J Clin Invest* 2005; **115**: 29-32 [PMID: 15630440 DOI: 10.1172/jci23928]

16 **Mas VR**, Fisher RA, Archer KJ, Maluf DG. Proteomics and liver fibrosis: identifying markers of fibrogenesis. *Expert Rev Proteomics* 2009; **6**: 421-431 [PMID: 19681677 DOI: 10.1586/epr.09.59]

17 **Younossi ZM**, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. *Hepatology* 2005; **42**: 665-674 [PMID: 16116632 DOI: 10.1002/hep.20838]

18 **Bell LN**, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. *Hepatology* 2010; **51**: 111-120 [PMID: 19885878 DOI: 10.1002/hep.23271]

19 **Verma S**, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver Int* 2013; **33**: 1398-1405 [PMID: 23763360 DOI: 10.1111/liv.12226]

20 **Li YY**. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. *World J Gastroenterol* 2012; **18**: 6546-6551 [PMID: 23236228 DOI: 10.3748/wjg.v18.i45.6546]

21 **Choe YG**, Jin W, Cho YK, Chung WG, Kim HJ, Jeon WK, Kim BI. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. *J Gastroenterol Hepatol* 2013; **28**: 678-683 [PMID: 23215811 DOI: 10.1111/jgh.12077]

22 **Gray J**, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. *BMC Cancer* 2009; **9**: 271 [PMID: 19656391 DOI: 10.1186/1471-2407-9-271]

23 **Sarrias MR**, Roselló S, Sánchez-Barbero F, Sierra JM, Vila J, Yélamos J, Vives J, Casals C, Lozano F. A role for human Sp alpha as a pattern recognition receptor. *J Biol Chem* 2005; **280**: 35391-35398 [PMID: 16030018 DOI: 10.1074/jbc.M505042200]

24 **Rodríguez-Suárez E**, Duce AM, Caballería J, Martínez Arrieta F, Fernández E, Gómara C, Alkorta N, Ariz U, Martínez-Chantar ML, Lu SC, Elortza F, Mato JM. Non-alcoholic fatty liver disease proteomics. *Proteomics Clin Appl* 2010; **4**: 362-371 [PMID: 21137056 DOI: 10.1002/prca.200900119]

25 **Luo S**, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. *Mol Cell Biol* 2006; **26**: 5688-5697 [PMID: 16847323 DOI: 10.1128/mcb.00779-06]

26 **Lee AS**. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. *Methods* 2005; **35**: 373-381 [PMID: 15804610 DOI: 10.1016/j.ymeth.2004.10.010]

27 **Kammoun HL**, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, Ferré P, Foufelle F. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. *J Clin Invest* 2009; **119**: 1201-1215 [PMID: 19363290 DOI: 10.1172/jci37007]

28 **Rector RS**, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, Ibdah JA. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. *J Hepatol* 2010; **52**: 727-736 [PMID: 20347174 DOI: 10.1016/j.jhep.2009.11.030]

29 **Ibdah JA**. "Oxidative stress-mediated mitochondrial dysfunction contributes to angiotension II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats". Note of concern. *Am J Pathol* 2009; **175**: 2709-2710 [PMID: 19965804 DOI: 10.2353/ajpath.2009.090921]

30 **Wei Y**, Clark SE, Thyfault JP, Uptergrove GM, Li W, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. *Am J Pathol* 2009; **174**: 1329-1337 [PMID: 19246643 DOI: 10.2353/ajpath.2009.080697]

31 **Nakagawa T**, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. *Cell* 2009; **137**: 560-570 [PMID: 19410549 DOI: 10.1016/j.cell.2009.02.026]

32 **Xu C**, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. *PLoS One* 2010; **5**: e11578 [PMID: 20644649 DOI: 10.1371/journal.pone.0011578]

33 **Sirota JC**, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. *Metabolism* 2013; **62**: 392-399 [PMID: 23036645 DOI: 10.1016/j.metabol.2012.08.013]

34 **Lv Q**, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. *PLoS One* 2013; **8**: e56864 [PMID: 23437258 DOI: 10.1371/journal.pone.0056864]

35 **Berezin AE**, Kremzer AA. Serum uric Acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. *Cardiol Res Pract* 2013; **2013**: 129369 [PMID: 23607043 DOI: 10.1155/2013/129369]

36 **Petta S**, Macaluso FS, Cammà C, Marco VD, Cabibi D, Craxì A. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. *Liver Int* 2012; **32**: 1443-1450 [PMID: 22764879 DOI: 10.1111/j.1478-3231.2012.02842.x]

37 **Johnson RJ**, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA. Sugar, uric acid, and the etiology of diabetes and obesity. *Diabetes* 2013; **62**: 3307-3315 [PMID: 24065788 DOI: 10.2337/db12-1814]

38 **Polyzos SA**, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Metabolism* 2011; **60**: 313-326 [PMID: 21040935 DOI: 10.1016/j.metabol.2010.09.003]

39 **Yoneda M**, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. *J Gastroenterol* 2007; **42**: 573-582 [PMID: 17653654 DOI: 10.1007/s00535-007-2060-x]

40 **Zimmermann E**, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Le Marchand-Brustel Y, Clement K, Van Gaal L, Sørensen TI, Jess T. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. *J Hepatol* 2011; **55**: 660-665 [PMID: 21238518 DOI: 10.1016/j.jhep.2010.12.017]

41 **Trak-Smayra V**, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH, Bedossa P, Paradis V. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. *Gut* 2009; **58**: 825-832 [PMID: 18403495 DOI: 10.1136/gut.2007.140087]

42 **Yu C**, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. *J Hepatol* 2012; **56**: 241-247 [PMID: 21756851 DOI: 10.1016/j.jhep.2011.05.027]

43 **Xu L**, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. *Gut* 2009; **58**: 1706-1707 [PMID: 19923352 DOI: 10.1136/gut.2009.186668]

44 **Kamada Y**, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y, Asazawa H, Nakayama K, Mizutani K, Fujii H, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. *PLoS One* 2013; **8**: e66328 [PMID: 23805214 DOI: 10.1371/journal.pone.0066328]

45 **Nakagawa T**, Moriwaki K, Terao N, Nakagawa T, Miyamoto Y, Kamada Y, Miyoshi E. Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. *J Proteome Res* 2012; **11**: 2798-2806 [PMID: 22483194 DOI: 10.1021/pr201154k]

46 **Bastrup-Birk S**, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. *PLoS One* 2013; **8**: e73119 [PMID: 24039869 DOI: 10.1371/journal.pone.0073119]

47 **Yoneda M**, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). *BMC Gastroenterol* 2008; **8**: 53 [PMID: 19014569 DOI: 10.1186/1471-230x-8-53]

48 **Karakas MF**, Buyukkaya E, Kurt M, Motor S, Akcay AB, Karakas E, Buyukkaya Ş, Sen N. Serum pentraxin-3 levels are associated with the severity of metabolic syndrome. *Med Princ Pract* 2013; **22**: 274-279 [PMID: 23146973 DOI: 10.1159/000343904]

49 **Kwak MS**, Kim D, Chung GE, Kang SJ, Park MJ, Kim YJ, Yoon JH, Lee HS. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. *Clin Mol Hepatol* 2012; **18**: 383-390 [PMID: 23323254 DOI: 10.3350/cmh.2012.18.4.383]

50 **Chang Y**, Ryu S, Zhang Y, Son HJ, Kim JY, Cho J, Guallar E. A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers. *PLoS One* 2012; **7**: e37241 [PMID: 22615952 DOI: 10.1371/journal.pone.0037241]

51 **Hjelkrem M**, Morales A, Williams CD, Harrison SA. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). *Aliment Pharmacol Ther* 2012; **35**: 1416-1423 [PMID: 22540836 DOI: 10.1111/j.1365-2036.2012.05114.x]

52 **Mayer M**. Association of serum bilirubin concentration with risk of coronary artery disease. *Clin Chem* 2000; **46**: 1723-1727 [PMID: 11067805]

53 **Collino M**, Pini A, Mugelli N, Mastroianni R, Bani D, Fantozzi R, Papucci L, Fazi M, Masini E. Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure. *Dis Model Mech* 2013; **6**: 1012-1020 [PMID: 23592614 DOI: 10.1242/dmm.011528]

54 **Sedlak TW**, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. *Pediatrics* 2004; **113**: 1776-1782 [PMID: 15173506]

55 **Li L**, Grenard P, Nhieu JT, Julien B, Mallat A, Habib A, Lotersztajn S. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. *Gastroenterology* 2003; **125**: 460-469 [PMID: 12891549]

56 **Kaneda H**, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. *J Gastroenterol Hepatol* 2006; **21**: 1459-1465 [PMID: 16911693 DOI: 10.1111/j.1440-1746.2006.04447.x]

57 **Suzuki A**, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. *Liver Int* 2005; **25**: 779-786 [PMID: 15998429 DOI: 10.1111/j.1478-3231.2005.01064.x]

58 **Santos VN**, Leite-Mór MM, Kondo M, Martins JR, Nader H, Lanzoni VP, Parise ER. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. *Braz J Med Biol Res* 2005; **38**: 747-753 [PMID: 15917956 DOI: /S0100-879x2005000500012]

59 **Yoneda M**, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. *J Gastroenterol* 2007; **42**: 375-381 [PMID: 17530362 DOI: 10.1007/s00535-007-2014-3]

60 **Gabrielli GB**, Capra F, Casaril M, Corrocher R, Colombari R, De Sandre G. Serum laminin P1 in chronic viral hepatitis: correlations with liver histological activity and diagnostic value. *Clin Chim Acta* 1996; **252**: 171-180 [PMID: 8853564]

61 **Peters L**, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. *PLoS One* 2013; **8**: e64283 [PMID: 23724041 DOI: 10.1371/journal.pone.0064283]

62 **Sakugawa H**, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. *World J Gastroenterol* 2005; **11**: 255-259 [PMID: 15633226]

63 **Charlton M**, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, Kendrick M, Thompson G, Que F, Swain J, Sarr M. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. *Hepatology* 2009; **49**: 1375-1384 [PMID: 19330863 DOI: 10.1002/hep.22927]

64 **Krishnan A**, Li X, Kao WY, Viker K, Butters K, Masuoka H, Knudsen B, Gores G, Charlton M. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. *Lab Invest* 2012; **92**: 1712-1725 [PMID: 23007134 DOI: 10.1038/labinvest.2012.121]

65 **Brown RD**, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. *Annu Rev Pharmacol Toxicol* 2005; **45**: 657-687 [PMID: 15822192 DOI: 10.1146/annurev.pharmtox.45.120403.095802]

66 **Engebretsen KV**, Lunde IG, Strand ME, Waehre A, Sjaastad I, Marstein HS, Skrbic B, Dahl CP, Askevold ET, Christensen G, Bjørnstad JL, Tønnessen T. Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. *FEBS J* 2013; **280**: 2382-2398 [PMID: 23480731 DOI: 10.1111/febs.12235]

67 **Wanninger J**, Walter R, Bauer S, Eisinger K, Schäffler A, Dorn C, Weiss TS, Hellerbrand C, Buechler C. MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis. *Exp Mol Pathol* 2011; **91**: 603-607 [PMID: 21791204 DOI: 10.1016/j.yexmp.2011.07.001]

68 **Manicone AM**, McGuire JK. Matrix metalloproteinases as modulators of inflammation. *Semin Cell Dev Biol* 2008; **19**: 34-41 [PMID: 17707664 DOI: 10.1016/j.semcdb.2007.07.003]

69 **Arthur MJ**. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2000; **279**: G245-G249 [PMID: 10915630]

70 **Mahmoud AA**, Bakir AS, Shabana SS. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. *Saudi J Gastroenterol* 2012; **18**: 327-333 [PMID: 23006461 DOI: 10.4103/1319-3767.101132]

71 **Lichtinghagen R**, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, Flemming P, Manns MP, Boeker KH. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. *Clin sci* (London)2003; **105**: 373-382 [PMID: 12760742 DOI: 10.1042/cs20030098]

72 **D'Amico F**, Consolo M, Amoroso A, Skarmoutsou E, Mauceri B, Stivala F, Malaponte G, Bertino G, Neri S, Mazzarino MC. Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. *Acta Histochem* 2010; **112**: 474-481 [PMID: 19604544 DOI: 10.1016/j.acthis.2009.05.005]

73 **de Meijer VE**, Sverdlov DY, Le HD, Popov Y, Puder M. Tissue-specific differences in inflammatory infiltrate and matrix metalloproteinase expression in adipose tissue and liver of mice with diet-induced obesity. *Hepatol Res* 2012; **42**: 601-610 [PMID: 22236199 DOI: 10.1111/j.1872-034X.2011.00960.x]

74 **Zhan YT**, An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. *World J Gastroenterol* 2010; **16**: 4652-4660 [PMID: 20872965]

75 **Maina V**, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. *Clin Sci* (Lond) 2012; **122**: 545-553 [PMID: 22142284 DOI: 10.1042/cs20110366]

76 **Inzaugarat ME**, Ferreyra Solari NE, Billordo LA, Abecasis R, Gadano AC, Cherñavsky AC. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. *J Clin Immunol* 2011; **31**: 1120-1130 [PMID: 21845516 DOI: 10.1007/s10875-011-9571-1]

77 **Ferreyra Solari NE**, Inzaugarat ME, Baz P, De Matteo E, Lezama C, Galoppo M, Galoppo C, Cherñavsky AC. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. *J Clin Immunol* 2012; **32**: 611-621 [PMID: 22228550 DOI: 10.1007/s10875-011-9635-2]

78 **Martel C**, Esposti DD, Bouchet A, Brenner C, Lemoine A. Non-alcoholic steatohepatitis: new insights from OMICS studies. *Curr Pharm Biotechnol* 2012; **13**: 726-735 [PMID: 22122481]

79 **Braunersreuther V**, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J Gastroenterol* 2012; **18**: 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727]

80 **Wieckowska A**, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. *Am J Gastroenterol* 2008; **103**: 1372-1379 [PMID: 18510618 DOI: 10.1111/j.1572-0241.2007.01774.x]

81 **Haukeland JW**, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. *J Hepatol* 2006; **44**: 1167-1174 [PMID: 16618517 DOI: 10.1016/j.jhep.2006.02.011]

82 **Sahin H**, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 682-690 [PMID: 20975742 DOI: 10.1038/nrgastro.2010.168]

83 **Kirovski G**, Dorn C, Huber H, Moleda L, Niessen C, Wobser H, Schacherer D, Buechler C, Wiest R, Hellerbrand C. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. *Exp Mol Pathol* 2011; **91**: 780-783 [PMID: 21855538 DOI: 10.1016/j.yexmp.2011.08.001]

84 **Alkhouri N**, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. *J Clin Gastroenterol* 2009; **43**: 985-989 [PMID: 19525859 DOI: 10.1097/MCG.0b013e3181a0998d]

85 **Yang Q**, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 2005; **436**: 356-362 [PMID: 16034410 DOI: 10.1038/nature03711]

86 **Saki F**, Karamizadeh Z, Honar N, Moravej H, Ashkani-Esfahani S, Namvar Shooshtarian MH. Association of Plasma Retinol Binding Protein-4 (RBP4) and Sonographic Grading of Fatty Liver in Obese Iranian Children. *Hepat Mon* 2012; **12**: e7103 [PMID: 23423766 DOI: 10.5812/hepatmon.7103]

87 **Graham TE**, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. *N Engl J Med* 2006; **354**: 2552-2563 [PMID: 16775236 DOI: 10.1056/NEJMoa054862]

88 **Christou GA**, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. *Horm Metab Res* 2012; **44**: 6-14 [PMID: 22205567 DOI: 10.1055/s-0031-1295491]

89 **Kotnik P**, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. *Eur J Endocrinol* 2011; **165**: 703-711 [PMID: 21835764 DOI: 10.1530/eje-11-0431]

90 **Esteve E**, Ricart W, Fernández-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. *Diabetes Care* 2009; **32** Suppl 2: S362-S367 [PMID: 19875582 DOI: 10.2337/dc09-S340]

91 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

92 **Kawaguchi T**, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012; **7**: e38322 [PMID: 22719876 DOI: 10.1371/journal.pone.0038322]

93 **Peng XE**, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. *PLoS One* 2012; **7**: e50256 [PMID: 23226254 DOI: 10.1371/journal.pone.0050256]

94 **Sookoian S**, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 2011; **53**: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]

95 **Dubuquoy C**, Burnol AF, Moldes M. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? *Clin Res Hepatol Gastroenterol* 2013; **37**: 30-35 [PMID: 22884299 DOI: 10.1016/j.clinre.2012.06.014]

96 **Wang CW**, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. *Liver Int* 2011; **31**: 1326-1331 [PMID: 21745282 DOI: 10.1111/j.1478-3231.2011.02526.x]

97 **Lallukka S**, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. *Diabetologia* 2013; **56**: 886-892 [PMID: 23334462 DOI: 10.1007/s00125-013-2829-9]

98 **Petit JM**, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, Bouillet B, Brindisi MC, Robin I, Gambert P, Verges B, Cercueil JP, Hillon P. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. *Liver Int* 2011; **31**: 1332-1336 [PMID: 21745307 DOI: 10.1111/j.1478-3231.2011.02566.x]

99 **Watt KD**, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, Thompson A, Krishnan A, Charlton MR. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. *Am J Transplant* 2013; **13**: 2450-2457 [PMID: 23859071 DOI: 10.1111/ajt.12355]

100 **Choi SS**, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. *Curr Opin Lipidol* 2008; **19**: 295-300 [PMID: 18460922 DOI: 10.1097/MOL.0b013e3282ff5e55]

101 **Yamaguchi K**, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. *Hepatology* 2007; **45**: 1366-1374 [PMID: 17476695 DOI: 10.1002/hep.21655]

102 **Chitraju C**, Trötzmüller M, Hartler J, Wolinski H, Thallinger GG, Haemmerle G, Zechner R, Zimmermann R, Köfeler HC, Spener F. The impact of genetic stress by ATGL deficiency on the lipidome of lipid droplets from murine hepatocytes. *J Lipid Res* 2013; **54**: 2185-2194 [PMID: 23740967 DOI: 10.1194/jlr.M037952]

103 **Fuchs CD**, Claudel T, Kumari P, Haemmerle G, Pollheimer MJ, Stojakovic T, Scharnagl H, Halilbasic E, Gumhold J, Silbert D, Koefeler H, Trauner M. Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. *Hepatology* 2012; **56**: 270-280 [PMID: 22271167 DOI: 10.1002/hep.25601]

104 **Duivenvoorden I**, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. *Diabetes* 2005; **54**: 664-671 [PMID: 15734841]

105 **Petersen KF**, Dufour S, Feng J, Befroy D, Dziura J, Man CD, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc Natl Acad Sci USA* 2006; **103**: 18273-18277 [PMID: 17114290 DOI: 10.1073/pnas.0608537103]

106 **Petersen KF**, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. *N Engl J Med* 2010; **362**: 1082-1089 [PMID: 20335584 DOI: 10.1056/NEJMoa0907295]

107 **Hyysalo J**, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, Lundbom N, Rissanen A, Krauss RM, Melander O, Orho-Melander M, Yki-Järvinen H. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2012; **27**: 951-956 [PMID: 22141340 DOI: 10.1111/j.1440-1746.2011.07045.x]

108 **Santoro N**, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B, Shaw MM, Groop L, Caprio S. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. *Hepatology* 2012; **55**: 781-789 [PMID: 22105854 DOI: 10.1002/hep.24806]

109 **Li H**, Xu R, Peng X, Wang Y, Wang T. Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis. *Mol Biol Rep* 2013; **40**: 3935-3942 [PMID: 23307301 DOI: 10.1007/s11033-012-2470-6]

110 **Fu D**, Cong X, Ma Y, Cai H, Cai M, Li D, Lv M, Yuan X, Huang Y, Lv Z. Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects. *PLoS One* 2013; **8**: e55727 [PMID: 23441155 DOI: 10.1371/journal.pone.0055727]

111 **Yang Z**, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C, Wu S, Hu R. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. *Mol Biol Rep* 2011; **38**: 1145-1150 [PMID: 20625834 DOI: 10.1007/s11033-010-0212-1]

112 **Tan HL**, Zain SM, Mohamed R, Rampal S, Chin KF, Basu RC, Cheah PL, Mahadeva S, Mohamed Z. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. *J Gastroenterol* 2013; Epub ahead of print [PMID: 23800943 DOI: 10.1007/s00535-013-0850-x]

113 **Lee HJ**, Su Y, Yin PH, Lee HC, Chi CW. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells. *Anticancer Res* 2009; **29**: 5057-5063 [PMID: 20044617]

114 **Yoneda M**, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, Kato S, Hosono K, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Abe Y, Kubota K, Saito S, Maeyama S, Wada K, Nakajima A. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). *BMC Gastroenterol* 2008; **8**: 27 [PMID: 18588668 DOI: 10.1186/1471-230x-8-27]

115 **Leone TC**, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. *PLoS Biol* 2005; **3**: e101 [PMID: 15760270 DOI: 10.1371/journal.pbio.0030101]

116 **Hui Y**, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D, Xiao-Bo L, Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. *Liver Int* 2008; **28**: 385-392 [PMID: 17999673 DOI: 10.1111/j.1478-3231.2007.01623.x]

117 **Lin YC**, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. *Am J Clin Nutr* 2013; **97**: 326-331 [PMID: 23269818 DOI: 10.3945/ajcn.112.046417]

118 **Lira VA**, Benton CR, Yan Z, Bonen A. PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. *Am J Physiol Endocrinol Metab* 2010; **299**: E145-E161 [PMID: 20371735 DOI: 10.1152/ajpendo.00755.2009]

119 **Gawrieh S**, Marion MC, Komorowski R, Wallace J, Charlton M, Kissebah A, Langefeld CD, Olivier M. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. *Dig Dis Sci* 2012; **57**: 952-957 [PMID: 22160635 DOI: 10.1007/s10620-011-1994-2]

120 **Cao CY**, Li YY, Zhou YJ, Nie YQ, Wan YJ. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease. *Tohoku J Exp Med* 2012; **227**: 253-262 [PMID: 22820754]

121 **Bhatt SP**, Nigam P, Misra A, Guleria R, Luthra K, Pandey RM, Pasha MA. Association of peroxisome proliferator activated receptor-γ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. *Gene* 2013; **512**: 143-147 [PMID: 23031808 DOI: 10.1016/j.gene.2012.09.067]

122 **Greenberg AS**, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. *Am J Clin Nutr* 2006; **83**: 461S-465S [PMID: 16470013]

123 **Hernaez R**, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, Harris TB, Nguyen T, Kamel IR, Bonekamp S, Eberhardt MS, Clark JM, Kao WH, Speliotes EK. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third national health and nutrition examination survey. *Clin Gastroenterol Hepatol* 2013; **11**: 1183-1190.e2 [PMID: 23416328 DOI: 10.1016/j.cgh.2013.02.011]

124 **Araneta MR**, Barrett-Connor E. Adiponectin and ghrelin levels and body size in normoglycemic Filipino, African-American, and white women. *Obesity* (Silver Spring) 2007; **15**: 2454-2462 [PMID: 17925471 DOI: 10.1038/oby.2007.291]

125 **Finelli C**, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? *World J Gastroenterol* 2013; **19**: 802-812 [PMID: 23430039 DOI: 10.3748/wjg.v19.i6.802]

126 **Musso G**, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. *Hepatology* 2008; **47**: 1167-1177 [PMID: 18311774 DOI: 10.1002/hep.22142]

127 **Wong VW**, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, So WY, Tse AM, Chan FK, Sung JJ, Chan HL. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. *J Gastroenterol Hepatol* 2008; **23**: 914-921 [PMID: 18565022 DOI: 10.1111/j.1440-1746.2008.05344.x]

128 **Zhang H**, Mo X, Hao Y, Gu D. Association between polymorphisms in the adiponectin gene and cardiovascular disease: a meta-analysis. *BMC Med Genet* 2012; **13**: 40 [PMID: 22639977 DOI: 10.1186/1471-2350-13-40]

129 **Xi B**, He D, Wang Q, Xue J, Liu M, Li J. Common polymorphisms (rs2241766 and rs1501299) in the ADIPOQ gene are not associated with hypertension susceptibility among the Chinese. *Mol Biol Rep* 2012; **39**: 8771-8775 [PMID: 22714914 DOI: 10.1007/s11033-012-1739-0]

130 **Han LY**, Wu QH, Jiao ML, Hao YH, Liang LB, Gao LJ, Legge DG, Quan H, Zhao MM, Ning N, Kang Z, Sun H. Associations between single-nucleotide polymorphisms (+45T& gt; G, +276G& gt; T, -11377C& gt; G, -11391G& gt; A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis. *Diabetologia* 2011; **54**: 2303-2314 [PMID: 21638131 DOI: 10.1007/s00125-011-2202-9]

131 **Li Y**, Yang Y, Shi L, Li X, Zhang Y, Yao Y. The association studies of ADIPOQ with type 2 diabetes mellitus in Chinese populations. *Diabetes Metab Res Rev* 2012; **28**: 551-559 [PMID: 22539443 DOI: 10.1002/dmrr.2309]

132 **Zhou W**, Liu Y, Zhong DW. Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis. *Tumour Biol* 2013; **34**: 493-504 [PMID: 23143890 DOI: 10.1007/s13277-012-0574-1]

133 **Xu Y**, He B, Pan Y, Gu L, Nie Z, Chen L, Li R, Gao T, Wang S. The roles of ADIPOQ genetic variations in cancer risk: evidence from published studies. *Mol Biol Rep* 2013; **40**: 1135-1144 [PMID: 23065236 DOI: 10.1007/s11033-012-2154-2]

134 **Muhidin SO**, Magan AA, Osman KA, Syed S, Ahmed MH. The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. *J Obes* 2012; **2012**: 637538 [PMID: 23304464 DOI: 10.1155/2012/637538]

135 **Lu H**, Sun J, Sun L, Shu X, Xu Y, Xie D. Polymorphism of human leptin receptor gene is associated with type 2 diabetic patients complicated with non-alcoholic fatty liver disease in China. *J Gastroenterol Hepatol* 2009; **24**: 228-232 [PMID: 18713300 DOI: 10.1111/j.1440-1746.2008.05544.x]

136 **Swellam M**, Hamdy N. Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor. *IUBMB Life* 2012; **64**: 180-186 [PMID: 22215535 DOI: 10.1002/iub.597]

137 **Dubern B**, Clement K. Leptin and leptin receptor-related monogenic obesity. *Biochimie* 2012; **94**: 2111-2115 [PMID: 22627381 DOI: 10.1016/j.biochi.2012.05.010]

138 **Perfield JW**, Ortinau LC, Pickering RT, Ruebel ML, Meers GM, Rector RS. Altered Hepatic Lipid Metabolism Contributes to Nonalcoholic Fatty Liver Disease in Leptin-Deficient Ob/Ob Mice. *J obes* 2013; **2013**: 8 [DOI: 10.1155/2013/296537]

139 **Zain SM**, Mohamed Z, Mahadeva S, Cheah PL, Rampal S, Chin KF, Mahfudz AS, Basu RC, Tan HL, Mohamed R. Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene. *J Gastroenterol Hepatol* 2013; **28**: 873-879 [PMID: 23278404 DOI: 10.1111/jgh.12104]

140 **Tilg H**. The role of cytokines in non-alcoholic fatty liver disease. *Dig Dis* 2010; **28**: 179-185 [PMID: 20460908 DOI: 10.1159/000282083]

141 **Coulon S**, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. *Cytokine* 2012; **59**: 442-449 [PMID: 22658783 DOI: 10.1016/j.cyto.2012.05.001]

142 **Wang JK**, Feng ZW, Li YC, Li QY, Tao XY. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. *J Gastroenterol Hepatol* 2012; **27**: 670-676 [PMID: 22097889 DOI: 10.1111/j.1440-1746.2011.06978.x]

143 **Dongiovanni P**, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. *Gut* 2010; **59**: 267-273 [PMID: 20176643 DOI: 10.1136/gut.2009.190801]

144 **Aparicio-Vergara M**, Hommelberg PP, Schreurs M, Gruben N, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DP, Hofker MH. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. *Hepatology* 2013; **57**: 566-576 [PMID: 22941955 DOI: 10.1002/hep.26046]

145 **Giannitrapani L**, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. *World J Gastroenterol* 2013; **19**: 2449-2455 [PMID: 23674845 DOI: 10.3748/wjg.v19.i16.2449]

146 **Carulli L**, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, De Palma M, Lonardo A, Ricchi M, Bertolotti M, Carulli N, Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. *Dig Liver Dis* 2009; **41**: 823-828 [PMID: 19403348 DOI: 10.1016/j.dld.2009.03.005]

**P-Reviewers:** De Petro G, Gerova VA **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

Table 1 Proteomic studies of non-alcoholic fatty liver disease

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Protein Categories** | **Protein Markers** | **Ref.** | **Year** | **Findings** | **Implications** |
| Protein carrier | Apolipoproteins | Choe *et al*[[21](#_ENREF_21)] | 2013 | Independent association between ApoB/ApoA1 ratio and NAFLD. | * NAFLD is the hepatic manifestation of MetS. * ApoB/ApoA1 ratio as a predictable marker of cardiovascular risk in NAFLD. |
| CD5L | Gray *et al*[[22](#_ENREF_22)] | 2009 | * Identified a pattern of serum apolipoproteins and CD5L to distinguish between pre-cirrhotic NAFLD and cirrhotic NAFLD. * Identified CD5L as poor biomarkers for HCC. | Possiblility of different trigger factors for the progression of NAFLD, NASH to HCC. |
| Metabolic pathways | CPS1 | Rodríguez-Suárez *et al*[[24](#_ENREF_24)] | 2010 | Decreased in NASH compared to control patients. | Down-regulation of CPS1 may lead to an increase of uric acid[[31](#_ENREF_31)]. |
| GRP78 | Rodríguez-Suárez *et al*[[24](#_ENREF_24)] | 2010 | Decreased in NASH compared to control patients. | Increased *de novo* lipogenesis might play a role in NAFLD pathogenesis[[27](#_ENREF_27)]. |
| Uric Acid | Sirota *et al*[[33](#_ENREF_33)] | 2013 | Association of increased serum uric acid level and severity of NAFLD. | Mitochondrial oxidative damage could contribute to hepatic steatosis. |
| Acute phase protein | hs-CRP | Yoneda *et al*[[39](#_ENREF_39)] | 2007 | Increased hs-CRP serum level in advanced NASH. | * Acute phase proteins may have an immediate role in hepatocytes injuries predictive markers. * Serum levels of acute phase proteins do not necessary reflect the severity of disease. * NAFLD progression has a more complex underlying protein mechanism. |
| Haemoglobin | Yu *et al*[[42](#_ENREF_42)] | 2012 | Association of elevated serum haemoglobin levels and prevalence of NAFLD. |
| Fuc-Hpt | Kamada *et al*[[44](#_ENREF_44)] | 2013 | Stepwise increased with increasing hepatocyte ballooning scores in biopsy-proven NAFLD patients. |
| PTX-3 | Yoneda *et al*[[47](#_ENREF_47)] | 2008 | A profound elevation of plasma PTX-3 level in NASH patients. |
| Anti-inflammatory and anti-oxidant | Bilirubin | Kwak *et al*[[49](#_ENREF_49)] | 2012 | An inverse relationship between total serum bilirubin level and the prevalence of NAFLD. | Bilirubin has antioxidant, anti-inﬂammatory and anti-ﬁbrogenic effects. |
| Extracellular matrix | Hyaluronic acid | Kaneda *et al*[[56](#_ENREF_56)] | 2006 | Association of increased serum concentration of ECM components and degree of fibrosis in NAFLD. | An imbalance of ECM production and degradation could lead to fibrogenensis, but not specific to NAFLD. |
| Type IV collagen 7S | Yoneda *et al*[[59](#_ENREF_59)] | 2007 |
| Laminin | Gabrielli *et al*[[60](#_ENREF_60)] | 1996 |
| Lumican | Krishnan *et al*[[64](#_ENREF_64)] | 2012 | Over-expressed of Lumican with increasing severity of NAFLD and NASH. | Unregulated tissue remodelling and ﬁbrogenesis could contribute to the progression of NAFLD |
| MMP-9 | D'Amico *et al*[[72](#_ENREF_72)] | 2010 | * An increase in serum MMP-9 levels in NASH and hepatitis C infected patients * Demonstrated a difference of immunolabelling patterns between NASH and hepatitis C infected liver | Possibility of a different pathophysiological involvement of protease in the ﬁbrogenesis of different liver etiology. |
| Wanninger *et al* [[67](#_ENREF_67)] | 2011 | * Association of MMP-9 activity and hepatic inflammation. * A negative correlation of MMP-9 activity and serum adiponectin. | Possibility of peripheral adipocytes involvement in NAFLD progression. |
| Immune cells and cytokines | CCL2/MCP1 | Haukeland *et al* [[81](#_ENREF_81)] | 2006 | Demonstrated an increasing level of CCL2/MCP1, from healthy controls to NASH. | The lipid accumulation from visceral tissue and hepatocellular could be responsible for the recruitment of immune cells. |
| RBP4 | Bell *et al* [[18](#_ENREF_18)] | 2010 | A decreased expression of RBP4 with increasing NAFLD severity. | RBP4 could contribute to the fibrogenesis pathway in NAFLD. |
| Alkhouri *et al*[[84](#_ENREF_84)] | 2009 | An inverse relationship between RBP4 levels and liver fibrosis. |
| Graham *et al*[[87](#_ENREF_87)] | 2006 | Association of increased serum RBP4 with T2DM and a decreased expression of glucose transporter 4. | RBP4 is associated with insulin resistance and T2DM. |
| Christou *et al*[[88](#_ENREF_88)] | 2012 | * RBP4 has the ability to induce insulin resistance in the adipose tissue. * Circulating RBP4 can be influenced by non-metabolic conditions and interventions. | The association of RBP4 level and MetS is still not conclusive and should be interpret with caution. |

NAFLD: non-alcoholic fatty liver disease; MetS: metabolic syndrome; NASH: non-alcoholic steatohepatitis; HCC: hepatocellular carcinoma; CPS1: carbamoyl phosphate synthase 1; hs-CRP: high sensitivity C-reactive protein; PTX-3: Pentraxin 3; ECM: extracellular matrix; MMP: matrix metalloproteinases; CCL2/MCP1: CC-chemokine ligand 2/monocyte chemo-attractant protein-1; T2DM: type II diabetes mellitus.

Table 2 Genomic studies of non-alcoholic fatty liver disease

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene Categories** | **Genes** | **Ref.** | **Year** | **Findings** | **Implications** |
| Gene that affect lipolysis | PNPLA3 | Romeo *et al*[[91](#_ENREF_91)] | 2008 | PNPLA3 polymorphism is strongly associated with the pathogenic status of NAFLD in different populations. | A well established link between PNPLA3 and NAFLD progression. |
| Sookoian *et al*[[94](#_ENREF_94)] | 2011 | GG genotype of PNPLA3 (rs738409; I148M) exerts a stronger effect on hepatic lipids accumulations. | Identified the patients group who is more susceptible to aggressive diseases. |
| Dubuquoy *et al*[[95](#_ENREF_95)] | 2013 | PNPLA3 polymorphism is more likely to influence lipid content and liver disease severity but not insulin resistance. | A less clear association of insulin resistance with PNPLA3 polymorphism. |
| ATGL | Chitraju *et al*[[102](#_ENREF_102)] | 2013 | Demonstrated that ATGL-KO animal models have high insulin sensitivity. | An accumulation of TG could be a protective mechanism in NAFLD. |
| ApoC3 | Petersen *et al*[[106](#_ENREF_106)] | 2010 | ApoC3 polymorphism is associated with NAFLD and insulin resistance in Indian populations. | Highlighted the ethnic differences in ApoC3 polymorphism and disease susceptibility. |
| Hyysalo *et al*[[107](#_ENREF_107)] | 2012 | ApoC3 polymorphism does not associated with NAFLD in Finnish populations. |
| GCKR | Santora *et al*[[108](#_ENREF_108)] | 2012 | GCKR polymorphism is associated with NAFLD. | Lipogenesis pathway plays a role in NAFLD pathogenesis. |
| Tan *et al*[[112](#_ENREF_112)] | 2013 | Interactions of GCKR and PNPLA3 genes can increase susceptibility to NAFLD. |
| PPARGC1A and PPAR-γ | Hui *et al*[[116](#_ENREF_116)] | 2008 | * PPARGC1A gene polymorphism is not associated with NAFLD. * PPAR-α is associated with NAFLD susceptibility. | * The PGC-1α and PPAR-γ pathway play a role in NAFLD progression. * The role of PCG-1α (encoded by the PPARGC1A gene) in MetS is less clear than PPAR-γ. |
| Gawrieh *et al*[[119](#_ENREF_119)] | 2012 | PPAR-γ polymorphism is associated with NAFLD. |
| Genes that affect adipokines | Adiponectin | Musso *et al*[[126](#_ENREF_126)] | 2008 | Adiponectin gene polymorphism is associated with the presence of NAFLD. | *De novo* lipogenesis plays a role in NAFLD. |
| Han *et al*[[130](#_ENREF_130)] | 2011 | Adiponectin gene polymorphism does not influence the development of T2DM | Possibility of different mechanisms for insulin sensitising in NAFLD. |
| Li[[20](#_ENREF_20)] | 2012 |
| Muhidin *et al*[[134](#_ENREF_134)] | 2012 | Demonstrated a correlation between NAFLD and colorectal cancer. | Raises the possibility and association of anti-inflammatory effect in NAFLD progression and oncological disease. |
| LEP and LEPR | Zain *et al*[[139](#_ENREF_139)] | 2013 | Demonstrated an association between variants of LEPR and PNPLA3. | Patients with mutations of both LEPR and PNPLA3 are highly susceptible to NAFLD. |
| Genes that affect cytokines | TNF-α | Wang *et al*[[142](#_ENREF_142)] | 2012 | Polymophisms of TNF-α are associated with the susceptibility to NAFLD. | * Insulin resistance and hepatic inflammation are related. * Insulin signal transduction pathway does contribute to the progression of NAFLD. |
| IL-6 | Carulli *et al*[[146](#_ENREF_146)] | 2009 | Polymorphisms of IL-6 are more prevalent in NAFLD and associated with insulin resistance. |
| Giannitrapani *et al*[[145](#_ENREF_145)] | 2013 | Polymorphisms of IL-6 are unlikely to associate with insulin resistance. |

NAFLD: non-alcoholic fatty liver disease; MetS: metabolic syndrome; NASH: non-alcoholic steatohepatitis; HCC: hepatocellular carcinoma; CPS1: carbamoyl phosphate synthase 1; hs-CRP: high sensitivity C-reactive protein; PTX-3: Pentraxin 3; ECM: extracellular matrix; MMP: matrix metalloproteinases; CCL2/MCP1: CC-chemokine ligand 2/monocyte chemo-attractant protein-1; T2DM: type II diabetes mellitus.